Given that the ADAM10 inhibitor reduced the inflammation of murine aortic wall and the formation of AAA and enhanced expression of miR-103a and/or interfering with ADAM10 function might be a promising AAA therapeutic strategy. Here, ADAM10 is linked to triple-A syndrome.